Premium
Overexpression of the human major vault protein in astrocytic brain tumor cells
Author(s) -
Berger Walter,
SpieglKreinecker Sabine,
Buchroithner Johanna,
Elbling Leonilla,
Pirker Christine,
Fischer Johannes,
Micksche Michael
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.1486
Subject(s) - biology , pathology , western blot , neuroblastoma , glioma , medulloblastoma , etoposide , cancer research , cell culture , immunohistochemistry , microbiology and biotechnology , gene , medicine , chemotherapy , immunology , genetics , biochemistry
Evidence has shown that the major human vault protein (MVP), which is identical to lung resistance‐related protein (LRP), may be causally involved in a special type of multidrug resistance (MDR). The purpose of this study was to investigate the expression and cellular localization of MVP in cells derived from brain tumors and other tumors of neuroectodermal origin. Using both established cell lines ( n = 22) and primary explants ( n = 30), we show that a distinct overexpression of the MVP gene at the mRNA (RT‐PCR) and protein (Western blot) levels is a characteristic feature of cells derived from astrocytic brain tumors. Primary cultures obtained from meningioma specimens also expressed high MVP levels, in contrast to neuroblastoma and medulloblastoma cells, which rarely contained detectable amounts of MVP. Normal human astrocytes cultured in vitro expressed MVP, although at low amounts compared with most malignant cell types. Basal MVP expression correlated with resistance against diverse antineoplastic drugs including anthracyclins, cisplatin and etoposide. By Western blot, MVP was also detected in all tumor samples taken from 7 glioma and 3 meningioma patients. Taken together, these data suggest overexpression of MVP as one explanation for the low efficacy of chemotherapeutic treatment of astrocytic brain tumors. © 2001 Wiley‐Liss, Inc.